Growing community of inventors

Boulogne Billancourt, France

Xavier Guillonneau

Average Co-Inventor Count = 4.61

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 1

Xavier GuillonneauJose-Alain Sahel (4 patents)Xavier GuillonneauFlorian Sennlaub (4 patents)Xavier GuillonneauOlivier Levy (1 patent)Xavier GuillonneauPhilippe Karoyan (1 patent)Xavier GuillonneauJosé-Alain Sahel (2 patents)Xavier GuillonneauNaziha Marrakchi (1 patent)Xavier GuillonneauBertrand Callippe (1 patent)Xavier GuillonneauErij Messadi (1 patent)Xavier GuillonneauFadoua Montassar (1 patent)Xavier GuillonneauMichael Housset (1 patent)Xavier GuillonneauXavier Guillonneau (4 patents)Jose-Alain SahelJose-Alain Sahel (44 patents)Florian SennlaubFlorian Sennlaub (10 patents)Olivier LevyOlivier Levy (5 patents)Philippe KaroyanPhilippe Karoyan (5 patents)José-Alain SahelJosé-Alain Sahel (2 patents)Naziha MarrakchiNaziha Marrakchi (1 patent)Bertrand CallippeBertrand Callippe (1 patent)Erij MessadiErij Messadi (1 patent)Fadoua MontassarFadoua Montassar (1 patent)Michael HoussetMichael Housset (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Centre National De La Recherche Scientifique (4 from 5,094 patents)

2. Institut National De La Sante Et De La Recherche Medicale (3 from 1,745 patents)

3. Sorbonne Université (3 from 240 patents)

4. Institut Pasteur De Tunis (1 from 6 patents)

5. Sarbonne Iniversié (1 from 1 patent)

6. Inserm (Institut National De La Sante Et De La Recherche Medicale) (42 patents)

7. Inserm (0 patent)


4 patents:

1. 11191807 - Lebecetin, a C-type lectin, as neovascularization inhibitor

2. 11142548 - Agents that activate CD47 and their use in the treatment of inflammation

3. 11072661 - Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof

4. 10519232 - Agents for use in the treatment of retinal inflammation

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/7/2026
Loading…